However, clinical trials targeting EGFR have shown poor benefits for breast cancer patients.[55] This could be partially due to deregulated EGFR degradation and reduced ubiquitination as well as enhanced EGFR recycling in EGFR‐TKI resistant cells.[58] In our results, SGCE loss increased EGFR ubiquitination and lysosomal degradation and reduced EGFR recycling, implying that SGCE may play an important role in EGFR‐TKI resistance. The gene discussed is EGFR; the disease is breast carcinoma.